a single arm clinical study on immune checkpoint inhibitors (anti-PD-1 or anti-PD-L1) combined with Anlotinib in 2nd-line for advanced NSCLC treated with immunotherapy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000038841

Enrollment

Unknown

Registered

2020-10-05

Start date

2020-10-30

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

PD-1/PD-L1 inhibitors combined with anlotinib group:PD-1/PD-L1 inhibitors combined with anlotinib

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: A. Aged 18 to 75 years; B. Histologically confirmed non-small cell lung cancer; C. Fuilure of immunotherapy in first-line; D. PS score 0-1; E. Expecter survival >= 3months; F. Normal function of main organs; G. Childbearing age women must Contraception; H. Voluntary participation and sign the informed consent.

Exclusion criteria

Exclusion criteria: A. Concomitant with other tumors; B. Accompanied with server immune-related adverse events, for example,pneumonitis; C. Accompanied with remarkable hemoptysis symptoms; D. The presence of autoimmune diseases, or the presence of comorbidities requiring long-term use of hormones; E. Difficulty to communication and long-term follow-up; F. Other conditions not suitable for paticipation.

Design outcomes

Primary

Measure	Time frame
ORR;safety;	—

Secondary

Measure	Time frame
DCR;PFS;PFS;OS;	—

Countries

China

Contacts

Public Contactdingzhenyu

dingzhenyu@scu.edu.cn+86 18980601957

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026